Oncology-focused biotechnology company IDEAYA Biosciences Inc revealed on Tuesday the election of Bao Truong as vice president as head of its regulatory affairs.

More recently, Bao was employed as vice president, head of regulatory affairs at Ignyta, where she helped drive entrectinib's clinical development plan (from Phase 1/Expansion to registration-enabling single-arm global Phase 2 basket trial) with potential to support both tissue specific and tissue agnostic indications.

Previously, Bao has served as head of regulatory affairs at Aragon Pharmaceuticals and Seragon Pharmaceuticals.

In the past, Bao was a global regulatory lead at Genentech for Erivedge, the first FDA- approved therapeutic for advanced, basal cell carcinoma as well as held positions of increasing responsibility for multiple oncology products, including Kadcyla, Gazyva, Tarceva and Herceptin.

At the start of her career, Bao was part of the oncology research at University of California, San Diego and University of California, San Francisco.